Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dynavax’s Vasculitis Case With Heplisav Could Be Random

This article was originally published in The Pink Sheet Daily

Executive Summary

Response to FDA on hepatitis B vaccine clinical hold points to a case in the control as well as the drug arm.

You may also be interested in...



GSK, Dynavax To Partner On TLR Compounds In Autoimmune, Inflammatory Disease

The latest option deal for GSK brings Dynavax $10 million upfront and potential milestones up to $200 million in each of four R&D programs.

GSK, Dynavax To Partner On TLR Compounds In Autoimmune, Inflammatory Disease

The latest option deal for GSK brings Dynavax $10 million upfront and potential milestones up to $200 million in each of four R&D programs.

Heplisav Phase III Data Good, But Timing Of Complete Response Still Unclear

Dynavax, Merck assembling package on HBV drug for FDA.

Topics

UsernamePublicRestriction

Register

PS068359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel